Prevention of Colic With the Probiotic Lactobacillus Reuteri
NCT ID: NCT02577133
Last Updated: 2015-10-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
478 participants
INTERVENTIONAL
2015-10-31
2016-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
There is now enough evidence for the treatment of colic using probiotics, especially Lactobacillus reuteri.
The investigators study aims to demonstrate the utility for the prevention of colic with L. reuteri and thereby avoid the problems caused by this pathology.
Objective: Compare the number of events of colic among infants with oral probiotic Lactobacillus reuteri during the first month of life versus infants with placebo
Study Design. Double blind, randomized, controlled, 492 neonates of 37-42 gestational age, breast or formula fed, will receive L. reuteri 5 drops (1x108 CFU) daily or placebo for 28 days. The investigators trial will be performed at Naval Hospital in Mexico City.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lactobacillus Reuteri Supplementation in the Treatment of Infantile Colic
NCT01887444
Control of Colic in Infants by Dietary Supplementation With the Probiotic Lactobacillus Reuteri
NCT01067027
Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic
NCT06462651
Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying Time in Infants With Colic
NCT05512234
Evaluating the Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic
NCT07190859
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is planned for October 2015 to October 2016 aiming newborns born population in Naval Hospital
Inclusion:
* Term Healthy Newborns (RN) ≥38 weeks and ≤ 41 weeks of gestation
* Appropriate weight for gestational age
* ≥than 8 Apgar at 5 minutes
* Egress at the first 24-48 hours of life of the newborn with the mother of hospital
* No congenital or physical abnormalities on physical examination at birth.
* Availability during the study period.
* Thorough understanding of the protocol by parents
* Informed Consent is signed by both parents.
Exclusion:
* Administration of antibiotics to the mother for a week before the birth of the newborn.
* Administration of probiotics newborn before inclusion or consumption by the mother during these last two trimesters.
* Medication Management newborn different routine prescribed at birth.
Elimination
* Loss of monitoring
* Abandonment by parents
* Diagnosis of allergy to cow's milk protein (confirmed by resolution of symptoms after switching to Formula hypo allergenic or free feeding cow's milk by the mother in breastfed children).
* Diagnosis of structural alterations or gastrointestinal illness to explain the symptoms of colic in the following months after the inclusion
Interventions:
The patients enrolled will receive probiotics (1000000000 CFU per day) or placebo every days for 28 days
Weekly, each patient will be called twice to interrogate the number of events colic as well as the different variables under study
After birth, on 15, 30, 45 and 60 of life will be cited for clinical examination and review and weight dropper bottle of probiotic
• Principal: Number of events or inconsolable crying
• Secondary: Average or evacuations / day Average or regurgitation / day Drugs to decrease excessive crying Medical reviews for excessive crying Changes feeding for excessive crying Level of satisfaction with the care of the newborn (numerical scale from 0: the worst possible, 10: completely satisfied)
• Universal variables
Weight:
Size:
Gender Weeks gestation Type of birth Feeding of formula / breast-
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lactobacillus reuteri group
Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
Lactobacillus reuteri DSM 17938
Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
Placebo group
Placebo (5 drops) for 28 days
Placebo
The placebo consisted of an identical bottle with distilled water
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lactobacillus reuteri DSM 17938
Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
Placebo
The placebo consisted of an identical bottle with distilled water
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Appropriate weight for gestational age
* ≥than 8 Apgar at 5 minutes
* Egress at the first 24-48 hours of life of the newborn with the mother of hospital
* No congenital or physical abnormalities on physical examination at birth.
* Availability during the study period.
* Thorough understanding of the protocol by parents
* Informed Consent is signed by both parents.
Exclusion Criteria
* Administration of probiotics newborn before inclusion or consumption by the mother during these last two trimesters.
* Medication Management newborn different routine prescribed at birth.
1 Day
1 Week
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital General Naval de Alta Especialidad - Escuela Medico Naval
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Jorge Ivan Valencia Moncada
Prevention of colic with the probiotic Lactobacillus reuteri DSM 17938 in Mexican infants: randomized, double-blind study
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Héctor Javier Varona Bobadilla, Dr.
Role: PRINCIPAL_INVESTIGATOR
Secretaria de Marina-Armada de México (Mexican Navy)
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Hyman PE, Milla PJ, Benninga MA, Davidson GP, Fleisher DF, Taminiau J. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology. 2006 Apr;130(5):1519-26. doi: 10.1053/j.gastro.2005.11.065.
WESSEL MA, COBB JC, JACKSON EB, HARRIS GS Jr, DETWILER AC. Paroxysmal fussing in infancy, sometimes called colic. Pediatrics. 1954 Nov;14(5):421-35. No abstract available.
Douglas P, Hill P. Managing infants who cry excessively in the first few months of life. BMJ. 2011 Dec 15;343:d7772. doi: 10.1136/bmj.d7772. No abstract available.
E. Ortega Páeza , D. Barroso Espaderob Flashes pediátricos AEpap Cólico del lactante Rev Pediatr Aten Primaria Supl. 2013;(22):81-7
Wolke D, Samara M, Alvarez Wolke M. Meta-analysis of fuss/cry durations and colic prevalence across countries: Proceedings of the11th International Infant Cry Research Workshop, June, 2011, The Netherlands.
Cohen GM, Albertini LW. Colic. Pediatr Rev. 2012 Jul;33(7):332-3; discussion 333. doi: 10.1542/pir.33-7-332. No abstract available.
Barr RG, Rotman A, Yaremko J, Leduc D, Francoeur TE. The crying of infants with colic: a controlled empirical description. Pediatrics. 1992 Jul;90(1 Pt 1):14-21.
Romanello S, Spiri D, Marcuzzi E, Zanin A, Boizeau P, Riviere S, Vizeneux A, Moretti R, Carbajal R, Mercier JC, Wood C, Zuccotti GV, Crichiutti G, Alberti C, Titomanlio L. Association between childhood migraine and history of infantile colic. JAMA. 2013 Apr 17;309(15):1607-12. doi: 10.1001/jama.2013.747.
Savino F, Cordisco L, Tarasco V, Calabrese R, Palumeri E, Matteuzzi D. Molecular identification of coliform bacteria from colicky breastfed infants. Acta Paediatr. 2009 Oct;98(10):1582-8. doi: 10.1111/j.1651-2227.2009.01419.x. Epub 2009 Jul 9.
de Weerth C, Fuentes S, Puylaert P, de Vos WM. Intestinal microbiota of infants with colic: development and specific signatures. Pediatrics. 2013 Feb;131(2):e550-8. doi: 10.1542/peds.2012-1449. Epub 2013 Jan 14.
Savino F, Cresi F, Pautasso S, Palumeri E, Tullio V, Roana J, Silvestro L, Oggero R. Intestinal microflora in breastfed colicky and non-colicky infants. Acta Paediatr. 2004 Jun;93(6):825-9.
Iacono G, Merolla R, D'Amico D, Bonci E, Cavataio F, Di Prima L, Scalici C, Indinnimeo L, Averna MR, Carroccio A; Paediatric Study Group on Gastrointestinal Symptoms in Infancy. Gastrointestinal symptoms in infancy: a population-based prospective study. Dig Liver Dis. 2005 Jun;37(6):432-8. doi: 10.1016/j.dld.2005.01.009. Epub 2005 Mar 2.
Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006 Apr;130(5):1377-90. doi: 10.1053/j.gastro.2006.03.008. No abstract available.
Charrois TL, Sandhu G, Vohra S. Probiotics. Pediatr Rev. 2006 Apr;27(4):137-9. doi: 10.1542/pir.27-4-137. No abstract available.
http://www.biogaia.com/lactobacillus-reuter
Talarico TL, Casas IA, Chung TC, Dobrogosz WJ. Production and isolation of reuterin, a growth inhibitor produced by Lactobacillus reuteri. Antimicrob Agents Chemother. 1988 Dec;32(12):1854-8. doi: 10.1128/AAC.32.12.1854.
Morelli L, Capurso L. FAO/WHO guidelines on probiotics: 10 years later. J Clin Gastroenterol. 2012 Oct;46 Suppl:S1-2. doi: 10.1097/MCG.0b013e318269fdd5. No abstract available.
Lifschitz C. Probiotics: Implications for Paediatric Health, Nestlé Nutrition Institute, South Asia Workshop Proceedings Vol. 1, Issue 1, 2013
Savino F, Pelle E, Palumeri E, Oggero R, Miniero R. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics. 2007 Jan;119(1):e124-30. doi: 10.1542/peds.2006-1222.
Savino F, Cordisco L, Tarasco V, Palumeri E, Calabrese R, Oggero R, Roos S, Matteuzzi D. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics. 2010 Sep;126(3):e526-33. doi: 10.1542/peds.2010-0433. Epub 2010 Aug 16.
Chumpitazi BP, Shulman RJ. Five probiotic drops a day to keep infantile colic away? JAMA Pediatr. 2014 Mar;168(3):204-5. doi: 10.1001/jamapediatrics.2013.5002. No abstract available.
Sung V, Collett S, de Gooyer T, Hiscock H, Tang M, Wake M. Probiotics to prevent or treat excessive infant crying: systematic review and meta-analysis. JAMA Pediatr. 2013 Dec;167(12):1150-7. doi: 10.1001/jamapediatrics.2013.2572.
Indrio F, Di Mauro A, Riezzo G, Civardi E, Intini C, Corvaglia L, Ballardini E, Bisceglia M, Cinquetti M, Brazzoduro E, Del Vecchio A, Tafuri S, Francavilla R. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: a randomized clinical trial. JAMA Pediatr. 2014 Mar;168(3):228-33. doi: 10.1001/jamapediatrics.2013.4367.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HGNAE-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.